Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK R&D chairman

Executive Summary

Senior VP-Worldwide Business Development & External Alliances in R&D Moncef Slaoui will succeed Tadataka Yamada as GlaxoSmithKline's R&D chairman. Yamada will resign from the post effective June 1 to serve as executive director of the Bill & Melinda Gates Foundation's Global Health Program. Yamada is credited with being the "principal architect" behind the transformation and improvement of the company's R&D engine. CEO J.P. Garnier recently touted GSK's pipeline as the largest in the pharmaceutical industry based on benchmark studies (1"The Pink Sheet" Sept. 26, 2005, p. 21)...

You may also be interested in...

GSK Senior VP-Worldwide Business Development

GlaxoSmithKline's incoming Senior VP-Worldwide Business Development, Research & Development Adrian Rawcliffe has a background in deal-making for GSK; Rawcliffe was most recently managing partner and president of GSK's venture capital business, SR One Ltd. He previously served as GSK's VP-Genetics & Discovery Deal Structuring and VP-Transactions & Ventures. Rawcliffe succeeds Moncef Slaoui, who moved up to the position of chairman of R&D earlier this year (1"The Pink Sheet" Feb. 13, 2006, In Brief)...

GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?

GlaxoSmithKline plans to end 2006 with six product launches and six regulatory filings, CEO J.P. Garnier said during a presentation at the Bear Stearns Healthcare conference in New York Sept. 13

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts